Fulcrum Therapeutics (FULC) Payables: 2019-2025
Historic Payables for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $2.9 million.
- Fulcrum Therapeutics' Payables fell 29.32% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year decrease of 48.89%. This contributed to the annual value of $1.2 million for FY2024, which is 57.78% down from last year.
- Per Fulcrum Therapeutics' latest filing, its Payables stood at $2.9 million for Q3 2025, which was up 63.11% from $1.8 million recorded in Q2 2025.
- Fulcrum Therapeutics' 5-year Payables high stood at $6.0 million for Q1 2022, and its period low was $1.2 million during Q4 2024.
- Moreover, its 3-year median value for Payables was $3.6 million (2023), whereas its average is $3.0 million.
- Its Payables has fluctuated over the past 5 years, first surged by 31.01% in 2023, then crashed by 60.93% in 2025.
- Quarterly analysis of 5 years shows Fulcrum Therapeutics' Payables stood at $4.8 million in 2021, then dropped by 24.02% to $3.6 million in 2022, then decreased by 24.22% to $2.8 million in 2023, then slumped by 57.78% to $1.2 million in 2024, then fell by 29.32% to $2.9 million in 2025.
- Its Payables was $2.9 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.5 million in Q1 2025.